AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial

OBJECTIVES: Phase I - To determine the optimal dose of each candidate (or combination of candidates) entered into the platform. Phase II - To determine the efficacy and safety of each candidate entered into the platform, compared to the current Standard of Care (SoC), and recommend whether it should...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffiths, Gareth, Fitzgerald, Richard, Jaki, Thomas, Corkhill, Andrea, Marwood, Ellice, Reynolds, Helen, Stanton, Louise, Ewings, Sean, Condie, Susannah, Wrixon, Emma, Norton, Andrea, Radford, Mike, Yeats, Sara, Robertson, Jane, Darby-Dowman, Rachel, Walker, Lauren, Khoo, Saye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303573/
https://www.ncbi.nlm.nih.gov/pubmed/32560744
http://dx.doi.org/10.1186/s13063-020-04473-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303573/
https://www.ncbi.nlm.nih.gov/pubmed/32560744
http://dx.doi.org/10.1186/s13063-020-04473-1

Ejemplares similares